At the 2024 U.S.-Taiwan Patient Day Innovation Forum, Shih Chung-liang from NHIA emphasized the benefits of transcatheter aortic valve implantation (TAVI), noting its less invasive nature and faster recovery compared to traditional surgery. As Taiwan’s population ages, the demand for TAVI is expected to rise, with Edwards Lifesciences leading advancements in this transformative technology.
The 2024 U.S.-Taiwan Patient Care Innovation Forum, co-hosted by AmCham Taiwan and AIT, showcased significant advancements in healthcare technology, including expanded hemodialysis, IMVAD for heart failure, and precision radioligand therapy. Keynote speakers emphasized the need for evolving policies to support these innovations and align with Taiwan’s healthcare goals.
Eli Lilly is advancing treatments in oncology, diabetes, immunology, obesity, and Alzheimer’s disease, with new therapies on the horizon. In Taiwan, Lilly is addressing growing concerns about dementia and obesity with significant R&D investment and plans to conduct over 60 clinical trials in 2024.
Taiwan’s new government is spearheading the “Healthy Taiwan” initiative to revamp the nation’s healthcare system with ambitious goals, including reducing cancer deaths by a third by 2030 and improving access to cutting-edge treatments. The plan involves increasing early disease detection, integrating new cancer drugs into the National Health Insurance (NHI), and enhancing overall health care services without overextending the NHI’s budget. Key elements include a comprehensive health exam for citizens, telemedicine, and a significant fund dedicated to advanced cancer treatments.
In Taiwan, the critical need for adult vaccinations is growing, yet many adults are not up-to-date due to financial barriers and lack of awareness. Vaccines like HPV and flu are often not covered by public health insurance for adults, leading to lower vaccination rates. Improving public education, making vaccines more accessible, and learning from successful vaccination strategies can enhance adult immunization and public health.
The Lai administration has bold ambitions for supporting cancer patients, but many details about the plan still remain uncertain. President Lai Ching-te gained widespread public interest during his election campaign last year by announcing his “Healthy Taiwan” policy focusing on disease prevention and health maintenance. The cornerstone of the plan is the establishment of a…
Taiwan will become a super-aged society by 2025, with at least 20% of the population aged 65 and above. This demographic shift, coupled with the impact of the pandemic, has caused the average life expectancy to fall below 80 years, with an “unhealthy life expectancy,” during which a person is dependent on the care of…
Lung cancer remains the leading cause of cancer mortality in Taiwan, with the five-year survival rate for advanced stages lingering around 10%. Despite significant advances in medical technology and treatment protocols worldwide, Taiwan faces a critical gap in aligning its National Health Insurance reimbursement with international standards for lung cancer treatment. “Despite some progress in…
As the world grapples with the challenges of vaccination, Moderna is revolutionizing vaccine coverage through cutting-edge technologies and strategic public health initiatives. Founded on technological innovation principles and deep scientific expertise, Moderna has leveraged its roots as a tech-driven biotech company to address critical gaps in vaccine coverage for the elderly and vulnerable populations. “At…
Taiwan’s National Health Insurance (NHI) system has long been a source of pride for Taiwan. However, the healthcare environment faces severe challenges due to long-term underinvestment and the significant increase in demand resulting from an aging population. The healthcare industry is confronted with serious shortages of medication, healthcare professionals, and investment. In 2023, the International…
